{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:47:11Z","timestamp":1782902831545,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Farmac\u00e9utica Espa\u00f1a S.A.","award":["Takeda Farmac\u00e9utica Espa\u00f1a S.A."],"award-info":[{"award-number":["Takeda Farmac\u00e9utica Espa\u00f1a S.A."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gaucher disease (GD) is a rare autosomal recessive genetic disorder. The clinical manifestations can be adequately managed with enzyme replacement therapy (ERT). The aim of this systematic literature review was to explore the safety and efficacy or effectiveness (depending on the type of evidence) profile of velaglucerase alfa in the treatment of paediatric patients with type 1 (GD1) and type 3 (GD3) GD across all paediatric ages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of the PubMed\/Medline and Embase databases, along with communications from international conferences, was conducted. The inclusion criteria comprised clinical studies published in either English or Spanish that assessed the therapeutic profile of velaglucerase alfa in patients with GD1 (primarily) and GD3 (exploratorily) of all paediatric ages (0\u201318 years). For each of the selected publications, data regarding the safety and efficacy\/effectiveness of this treatment were extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 539 publications were identified, of which 23 studies encompassing data from 159 paediatric patients were included. Nine studies (71 patients) provided information about the safety in paediatric patients with GD1, describing it as well tolerated. Regarding the efficacy\/effectiveness, 14 articles (113 patients) reported relevant data for the same subpopulation. Overall, improvements in haematological, visceral, skeletal, biomarker and health-related quality-of-life outcomes have been described in treatment-na\u00efve paediatric patients with GD1 who were initially treated with velaglucerase alfa, as well as maintained stability in patients previously treated with imiglucerase. Furthermore, it has been reported that the safety and efficacy\/effectiveness profile administered as home therapy enhances the quality of life for both patients and caregivers. The use of velaglucerase alfa in paediatric patients with GD3 was described in 7 publications (26 patients), suggesting a favourable safety profile, whereas its efficacy\/effectiveness was reported in 5 articles (16 patients). Improvements in the non-neurological manifestations of the disease were recorded in patients with GD3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review summarizes the limited evidence on velaglucerase alfa in paediatric patients with GD. Findings suggest that velaglucerase alfa may be a beneficial option for GD1 across all paediatric age groups (0\u201318 years). Additionally, it might be considered a therapeutic option for non-neurological GD3 symptoms, although evidence is scarce and exploratory, highlighting the need for further research in those patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04221-9","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:27:55Z","timestamp":1770298075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating the therapeutic profile of velaglucerase alfa in paediatric patients with Gaucher disease: a systematic review across all paediatric age groups"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5663-537X","authenticated-orcid":false,"given":"Javier","family":"de las Heras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-9179","authenticated-orcid":false,"given":"Jorge J","family":"Cebolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"de Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-1279","authenticated-orcid":false,"given":"Manuel","family":"G\u00f3mez-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4450-1213","authenticated-orcid":false,"given":"Isidro","family":"Vitoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"4221_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/jcm12010085","volume":"12","author":"G Castillon","year":"2022","unstructured":"Castillon G, Chang S-C, Moride Y. Global incidence and prevalence of Gaucher disease: A targeted literature review. JCM. 2022;12:85.","journal-title":"JCM"},{"key":"4221_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease Pathophysiology, clinical presentation and treatments. IJMS. 2017;18:441.","journal-title":"IJMS"},{"key":"4221_CR3","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.3390\/ijms23105842","volume":"23","author":"ML Furderer","year":"2022","unstructured":"Furderer ML, Hertz E, Lopez GJ, Sidransky E. Neuropathological features of Gaucher disease and Gaucher disease with parkinsonism. IJMS. 2022;23:5842.","journal-title":"IJMS"},{"key":"4221_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metabolism. 2018;13:107\u201318.","journal-title":"Expert Rev Endocrinol Metabolism"},{"key":"4221_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","volume":"136","author":"NJ Weinreb","year":"2022","unstructured":"Weinreb NJ, Goker-Alpan O, Kishnani PS, Longo N, Burrow TA, Bernat JA, et al. The diagnosis and management of Gaucher disease in pediatric patients: where do we go from here? Mol Genet Metab. 2022;136:4\u201321.","journal-title":"Mol Genet Metab"},{"key":"4221_CR6","doi-asserted-by":"crossref","unstructured":"Goker-Alpan O, Ivanova MM. Neuronopathic Gaucher disease: rare in the West, common in the East. J Inher Metab Disea. 2024;47:917\u2013934.","DOI":"10.1002\/jimd.12749"},{"key":"4221_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","volume":"68","author":"M Biegstraaten","year":"2018","unstructured":"Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, et al. Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Molecules Dis. 2018;68:203\u20138.","journal-title":"Blood Cells Molecules Dis"},{"key":"4221_CR8","doi-asserted-by":"publisher","first-page":"175023","DOI":"10.1016\/j.ejphar.2022.175023","volume":"926","author":"W Kong","year":"2022","unstructured":"Kong W, Lu C, Ding Y, Meng Y. Update of treatment for Gaucher disease. Eur J Pharmacol. 2022;926:175023.","journal-title":"Eur J Pharmacol"},{"key":"4221_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1194\/jlr.M021261","volume":"53","author":"SD Larsen","year":"2012","unstructured":"Larsen SD, Wilson MW, Abe A, Shu L, George CH, Kirchhoff P, et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res. 2012;53:282\u201391.","journal-title":"J Lipid Res"},{"key":"4221_CR10","unstructured":"European Medicines Agency (EMA). European technical data sheet of Cerdelga, INN-eliglustat [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cerdelga-epar-product-information_en.pdf"},{"key":"4221_CR11","unstructured":"European Medicines Agency (EMA). European technical data sheet of Yargesa, INN-miglustat [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yargesa-epar-product-information_en.pdf"},{"key":"4221_CR12","unstructured":"European Medicines Agency (EMA). European technical data sheet of Miglustat Dipharma 100\u00a0mg capsules [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/miglustat-dipharma-epar-product-information_en.pdf"},{"key":"4221_CR13","unstructured":"European Medicines Agency (EMA). European technical data sheet of Zavesca, INN-miglustat [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavesca-epar-product-information_en.pdf"},{"key":"4221_CR14","unstructured":"European Medicines Agency (EMA). European technical data sheet of Cerezyme, INN-imiglucerase [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cerezyme-epar-product-information_en.pdf"},{"key":"4221_CR15","unstructured":"European Medicines Agency (EMA). European technical data sheet of VPRIV\u00ae, INN-velaglucerase alfa [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vpriv-epar-product-information_en.pdf"},{"key":"4221_CR16","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/jcm13123588","volume":"13","author":"D Elstein","year":"2024","unstructured":"Elstein D, Belmatoug N, Bembi B, Deegan P, Fernandez-Sasso D, Giraldo P, et al. Twelve years of the Gaucher outcomes survey (GOS): Insights, Achievements, and lessons learned from a global patient registry. JCM. 2024;13:3588.","journal-title":"JCM"},{"key":"4221_CR17","first-page":"274","volume":"43","author":"LL Bennett","year":"2018","unstructured":"Bennett LL, Fellner C. Pharmacotherapy of Gaucher disease: current and future options. P T. 2018;43:274\u2013309.","journal-title":"P T"},{"key":"4221_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/17512433.2018.1549486","volume":"11","author":"P Gupta","year":"2018","unstructured":"Gupta P, Pastores G. Pharmacological treatment of pediatric Gaucher disease. Expert Rev Clin Pharmacol. 2018;11:1183\u201394.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4221_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-020-01520-7","volume":"15","author":"MM Andrade-Campos","year":"2020","unstructured":"Andrade-Campos MM, De Frutos LL, Cebolla JJ, Serrano-Gonzalo I, Medrano-Engay B, Roca-Espiau M, et al. Identification of risk features for complication in Gaucher\u2019s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis. 2020;15:256.","journal-title":"Orphanet J Rare Dis"},{"key":"4221_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","volume":"172","author":"P Kaplan","year":"2013","unstructured":"Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013;172:447\u201358.","journal-title":"Eur J Pediatr"},{"key":"4221_CR21","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"4221_CR22","unstructured":"Society for the Study of Inborn Errors of Metabolism (SSIEM) [Internet]. Available from: https:\/\/www.ssiem.org\/"},{"key":"4221_CR23","unstructured":"WORLDSymposium [Internet]. Available from: https:\/\/www.worldsymposia.org\/"},{"key":"4221_CR24","unstructured":"Society for Inherited Metabolic. Disorders (SIMD) [Internet]. Available from: https:\/\/www.simd.org\/"},{"key":"4221_CR25","doi-asserted-by":"publisher","first-page":"e87537","DOI":"10.7554\/eLife.87537","volume":"12","author":"M Basiri","year":"2023","unstructured":"Basiri M, Ghaffari ME, Ruan J, Murugesan V, Kleytman N, Belinsky G, et al. Osteonecrosis in Gaucher disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center. eLife. 2023;12:e87537.","journal-title":"eLife"},{"key":"4221_CR26","doi-asserted-by":"crossref","unstructured":"Becker-Cohen M, Revel\u2010Vilk S, Frydman D, Dinur T, Tiomkin M, Istaiti M, et al. Rapid home therapy infusion of velaglucerase alfa in na\u00efve patients with Gaucher disease. Internal Medicine Journal. 2023;imj.16179.","DOI":"10.1111\/imj.16179"},{"key":"4221_CR27","doi-asserted-by":"publisher","first-page":"100729","DOI":"10.1016\/j.ymgmr.2021.100729","volume":"27","author":"AR Stiles","year":"2021","unstructured":"Stiles AR, Huggins E, Fierro L, Jung S-H, Balwani M, Kishnani PS. The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease. Mol Genet Metabolism Rep. 2021;27:100729.","journal-title":"Mol Genet Metabolism Rep"},{"key":"4221_CR28","doi-asserted-by":"publisher","first-page":"e13718","DOI":"10.1111\/petr.13718","volume":"24","author":"L Soudek","year":"2020","unstructured":"Soudek L, Siddiqui I, Guerin A, Sondheimer N, Inbar-Feigenberg M, Abuquteish D, et al. Liver transplantation for Gaucher disease presenting as neonatal cholestasis: case report and literature review. Pediatr Transplant. 2020;24:e13718.","journal-title":"Pediatr Transplant"},{"key":"4221_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ymgmr.2017.10.011","volume":"14","author":"IVD Schwartz","year":"2018","unstructured":"Schwartz IVD, G\u00f6ker-Alpan \u00d6, Kishnani PS, Zimran A, Renault L, Panahloo Z, et al. Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher outcome survey. Mol Genet Metabolism Rep. 2018;14:73\u20139.","journal-title":"Mol Genet Metabolism Rep"},{"key":"4221_CR30","doi-asserted-by":"publisher","first-page":"232640981876556","DOI":"10.1177\/2326409818765564","volume":"6","author":"AAG Tantawy","year":"2018","unstructured":"Tantawy AAG, El-Beshlawy A, Marzouk I, Bavdekar A, Qin Y, Mellgard B, et al. Results from a 12-month open-label phase 1\/2 study of velaglucerase alfa in children and adolescents with type 3 Gaucher disease. J Inborn Errors Metabolism Screen. 2018;6:232640981876556.","journal-title":"J Inborn Errors Metabolism Screen"},{"key":"4221_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bcmd.2016.10.007","volume":"68","author":"A Zimran","year":"2018","unstructured":"Zimran A, Elstein D, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, et al. Treatment-na\u00efve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase Alfa by 4 years in phase 3 trials. Blood Cells Molecules Dis. 2018;68:153\u20139.","journal-title":"Blood Cells Molecules Dis"},{"key":"4221_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bcmd.2015.10.002","volume":"59","author":"H Ida","year":"2016","unstructured":"Ida H, Tanaka A, Matsubayashi T, Murayama K, Hongo T, Lee H-M, et al. A multicenter, open-label extension study of velaglucerase Alfa in Japanese patients with Gaucher disease: results after a cumulative treatment period of 24 months. Blood Cells Molecules Dis. 2016;59:140\u20137.","journal-title":"Blood Cells Molecules Dis"},{"key":"4221_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bcmd.2016.03.004","volume":"59","author":"GM Pastores","year":"2016","unstructured":"Pastores GM, Turkia HB, Gonzalez DE, Ida H, Tantawy AAG, Qin Y, et al. Development of anti-velaglucerase Alfa antibodies in clinical trial-treated patients with Gaucher disease. Blood Cells Molecules Dis. 2016;59:37\u201343.","journal-title":"Blood Cells Molecules Dis"},{"key":"4221_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2015.05.012","volume":"117","author":"L Smith","year":"2016","unstructured":"Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, et al. Long-term velaglucerase Alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase. Mol Genet Metab. 2016;117:164\u201371.","journal-title":"Mol Genet Metab"},{"key":"4221_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.23382","volume":"88","author":"HB Turkia","year":"2013","unstructured":"Turkia HB, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, et al. Velaglucerase Alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013;88:179\u201384.","journal-title":"Am J Hematol"},{"key":"4221_CR36","doi-asserted-by":"publisher","unstructured":"Vairo F, Netto C, Dorneles A, Mittelstadt S, Wilke M, Doneda D, et al. Enzyme replacement therapy in a patient with Gaucher disease type III: a paradigmatic case showing severe adverse reactions started a long time after the beginning of treatment. In: Zschocke J, Gibson KM, Brown G, Morava E, Peters V, editors. JIMD Reports - Volume 11 [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. pp. 1\u20136. Available from: https:\/\/doi.org\/10.1007\/8904_2013_214.","DOI":"10.1007\/8904_2013_214"},{"key":"4221_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ajh.23383","volume":"88","author":"A Zimran","year":"2013","unstructured":"Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, et al. Safety and efficacy of velaglucerase Alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013;88:172\u20138.","journal-title":"Am J Hematol"},{"key":"4221_CR38","doi-asserted-by":"crossref","unstructured":"Goker-Alpan O, Khan N, Friedman A, Ivanova M, Pathak R, Wright E. Treatment of infants and very young children with Gaucher disease with velaglucerase alfa: a single-center experience. J Inherit Metab Dis. 2023;46(S1):319.","DOI":"10.1016\/j.gimo.2023.100205"},{"key":"4221_CR39","doi-asserted-by":"crossref","unstructured":"Soudek L, Siddiqui I, Guerin A, Sondheimer N, Kamath BM, Walia J, et al. Tu1547 \u2013 Gaucher disease presenting as neonatal cholestasis with absence of neurological involvement. Case Report & Literature Review. Gastroenterology. 2019. p. 1052.","DOI":"10.1016\/S0016-5085(19)39589-7"},{"key":"4221_CR40","doi-asserted-by":"crossref","unstructured":"Elstein D, Zimran A, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, et al. Therapeutic goals and normal clinical values achieved within 4 years of initiating velaglucerase alfa in treatment-na\u00c3\u00afve patients with Gaucher disease in phase 3 studies. Molecular Genetics and Metabolism; 2016. p. 44.","DOI":"10.1016\/j.ymgme.2015.12.249"},{"key":"4221_CR41","doi-asserted-by":"crossref","unstructured":"Tantawy AAG, El-Beshlawy A, Marzouk I, Bavdekar A, Qin Y, Mellgard B, et al. Velaglucerase Alfa enzyme replacement therapy in children and adolescents with type 3 Gaucher disease: results of a 12-month multicenter, open-label phase 1\/2 study. Molecular Genetics and Metabolism; 2016. p. 111.","DOI":"10.1016\/j.ymgme.2015.12.456"},{"key":"4221_CR42","doi-asserted-by":"crossref","unstructured":"Bailey L, Ambruso D, Grabowski G, Burrow TA. Combination therapy (eliglustat\u2009+\u2009velaglucerase alfa) in a pediatric patient with Gaucher disease type 1 and hereditary spherocytosis. Molecular Genetics and Metabolism; 2015. p. 17.","DOI":"10.1016\/j.ymgme.2014.12.020"},{"key":"4221_CR43","doi-asserted-by":"crossref","unstructured":"Pastores G, Turkia H, Gonzalez DE, Ida H, Tantawy A, Lee H, et al. Development of anti-drug antibodies in Gaucher disease patients treated in velaglucerase alfa clinical trials. Blood Cells Mol Dis. 2016:59:37\u201343.","DOI":"10.1016\/j.bcmd.2016.03.004"},{"key":"4221_CR44","unstructured":"Pastores G, Hendrisksz C, Giugliani R, Braunlin E, Quartel A. Long-term velaglucerase alfa enzyme replacement therapy in children with type 1 Gaucher disease. J Inherit Metab Dis. 2014;37(S1):S153."},{"key":"4221_CR45","unstructured":"Giraldo P, Smith L, Harmatz P, Zahrieh D, Crombez E, Cohn G. Exploratory assessment of growth and bone marrow burden in a paediatric subgroup with type 1 Gaucher disease transitioned from imiglucerase to velaglucerase alfa. J Inherit Metab Dis. 2013;36(S2):S302."},{"key":"4221_CR46","unstructured":"Zimran A, Kishnani P, Elstein D, Gonzalez DE, Zahrieh D, Crombez E, et al. Exploratory assessment of growth and bone marrow burden in a pooled subgroup of paediatric patients with type 1 Gaucher disease treated with long-term velaglucerase alfa. J Inherit Metab Dis. 2013;36(S2):S302"},{"key":"4221_CR47","doi-asserted-by":"crossref","unstructured":"Zimran A, Gonzalez DE, Elstein D, Crombez E, Bhirangi K. 1261 enzyme replacement therapy with velaglucerase Alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease. Pediatric Research. 2010. p. 625.","DOI":"10.1203\/00006450-201011001-01261"},{"key":"4221_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/10600280221108443","volume":"57","author":"LP Leonart","year":"2023","unstructured":"Leonart LP, Fachi MM, B\u00f6ger B, da Silva MR, Szpak R, Lombardi NF, et al. A systematic review and meta-analyses of longitudinal studies on drug treatments for Gaucher disease. Ann Pharmacother. 2023;57:267\u201382.","journal-title":"Ann Pharmacother"},{"key":"4221_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13023-017-0587-3","volume":"12","author":"SA Jones","year":"2017","unstructured":"Jones SA, Rojas-Caro S, Quinn AG, Friedman M, Marulkar S, Ezgu F, et al. Survival in infants treated with sebelipase alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis. 2017;12:25.","journal-title":"Orphanet J Rare Dis"},{"key":"4221_CR50","first-page":"100328","volume":"25","author":"PS Kishnani","year":"2023","unstructured":"Kishnani PS, Kronn D, Brassier A, Broomfield A, Davison J, Hahn SH, et al. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report. Genet Sci. 2023;25:100328.","journal-title":"Genet Sci"},{"key":"4221_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13023-023-02623-7","volume":"18","author":"G Giuffrida","year":"2023","unstructured":"Giuffrida G, Markovic U, Condorelli A, Calafiore V, Nicolosi D, Calagna M, et al. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review. Orphanet J Rare Dis. 2023;18:27.","journal-title":"Orphanet J Rare Dis"},{"key":"4221_CR52","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.3390\/ijms24043945","volume":"24","author":"T Dinur","year":"2023","unstructured":"Dinur T, Bauer P, Beetz C, Cozma C, Becker-Cohen M, Istaiti M, et al. Contribution of glucosylsphingosine (Lyso-Gb1) to treatment decisions in patients with Gaucher disease. IJMS. 2023;24:3945.","journal-title":"IJMS"},{"key":"4221_CR53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2019.236083","volume":"106","author":"PB Tatiana Raskovalova","year":"2020","unstructured":"Tatiana Raskovalova PB, Deegan PK, Mistry E, Pavlova R, Yang A, Zimran, et al. Accuracy of Chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data. Haematol. 2020;106:437\u201345.","journal-title":"Haematol"},{"key":"4221_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13:61.","journal-title":"Orphanet J Rare Dis"},{"key":"4221_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mgg3.339","volume":"6","author":"M Cer\u00f3n-Rodr\u00edguez","year":"2018","unstructured":"Cer\u00f3n-Rodr\u00edguez M, Barajas\u2010Col\u00f3n E, Ram\u00edrez\u2010Devars L, Guti\u00e9rrez\u2010Camacho C, Salgado\u2010Loza JL. Improvement of life quality measured by Lansky score after enzymatic replacement therapy in children with Gaucher disease type 1. Molec Gen Gen Med. 2018;6:27\u201334.","journal-title":"Molec Gen Gen Med"},{"key":"4221_CR56","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13023-023-02844-w","volume":"18","author":"J Feng","year":"2023","unstructured":"Feng J, Gao Z, Shi Z, Wang Y, Li S. Patient-reported outcomes in Gaucher\u2019s disease: a systematic review. Orphanet J Rare Dis. 2023;18:244.","journal-title":"Orphanet J Rare Dis"},{"key":"4221_CR57","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13023-024-03256-0","volume":"19","author":"E McDool","year":"2024","unstructured":"McDool E, Powell P, Carlton J. Measuring health related quality of life (HRQoL) in lysosomal storage disorders (LSDs): a rapid scoping review of available tools and domains. Orphanet J Rare Dis. 2024;19:252.","journal-title":"Orphanet J Rare Dis"},{"key":"4221_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-021-02163-y","volume":"17","author":"D Elstein","year":"2022","unstructured":"Elstein D, Belmatoug N, Deegan P, G\u00f6ker-Alpan \u00d6, Hughes DA, Schwartz IVD, et al. Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials. Orphanet J Rare Dis. 2022;17:9.","journal-title":"Orphanet J Rare Dis"},{"key":"4221_CR59","doi-asserted-by":"publisher","first-page":"1618661","DOI":"10.1080\/20016689.2019.1618661","volume":"7","author":"N Germain","year":"2019","unstructured":"Germain N, Aball\u00e9a S, Toumi M. Measuring health-related quality of life in young children: how Far have we come? J Market Access Health Policy. 2019;7:1618661.","journal-title":"J Market Access Health Policy"},{"key":"4221_CR60","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.3390\/jcm12185913","volume":"12","author":"S Revel-Vilk","year":"2023","unstructured":"Revel-Vilk S, Mansfield R, Feder-Krengel N, Machtiger-Azoulay N, Kuter D, Szer J, et al. Real-World experiences with taliglucerase Alfa home infusions for patients with Gaucher disease: A global cohort study. JCM. 2023;12:5913.","journal-title":"JCM"},{"key":"4221_CR61","doi-asserted-by":"publisher","first-page":"e20180002","DOI":"10.1590\/2326-4594-jiems-2018-0002","volume":"7","author":"MV Brunelli","year":"2019","unstructured":"Brunelli MV, Rabhansl MM, Delacre C, Dankert MM, Cuevillas MV, Frias CT. Home-Based care for patients with lysosomal storage disease: experiences in Argentina. J Inborn Errors Metab Screen. 2019;7:e20180002.","journal-title":"J Inborn Errors Metab Screen"},{"key":"4221_CR62","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.hjdsi.2016.04.004","volume":"5","author":"JM Polinski","year":"2017","unstructured":"Polinski JM, Kowal MK, Gagnon M, Brennan TA, Shrank WH. Home infusion: Safe, clinically effective, patient preferred, and cost saving. Healthcare. 2017;5:68\u201380.","journal-title":"Healthcare"},{"key":"4221_CR63","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bcmd.2015.09.002","volume":"55","author":"D Elstein","year":"2015","unstructured":"Elstein D, Abrahamov A, Oz A, Arbel N, Baris H, Zimran A. 13,845 home therapy infusions with velaglucerase Alfa exemplify safety of velaglucerase Alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease. Blood Cells Molecules Dis. 2015;55:415\u20138.","journal-title":"Blood Cells Molecules Dis"},{"key":"4221_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymgme.2016.08.005","volume":"120","author":"D Elstein","year":"2017","unstructured":"Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, et al. Home infusion of intravenous velaglucerase alfa: experience from pooled clinical studies in 104 patients with type 1 Gaucher disease. Mol Genet Metab. 2017;120:111\u20135.","journal-title":"Mol Genet Metab"},{"key":"4221_CR65","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ajh.24040","volume":"90","author":"A Zimran","year":"2015","unstructured":"Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D. Seven-year safety and efficacy with velaglucerase Alfa for treatment\u2010na\u00efve adult patients with type 1 G Aucher disease. Am J Hematol. 2015;90:577\u201383.","journal-title":"Am J Hematol"},{"key":"4221_CR66","doi-asserted-by":"publisher","first-page":"100971","DOI":"10.1016\/j.ymgmr.2023.100971","volume":"35","author":"R Heinrich","year":"2023","unstructured":"Heinrich R, Claus F, Schoenfelder T. The patients` perspective on home-based infusion: a longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy. Mol Genet Metabolism Rep. 2023;35:100971.","journal-title":"Mol Genet Metabolism Rep"},{"key":"4221_CR67","doi-asserted-by":"publisher","first-page":"102478","DOI":"10.1016\/j.bcmd.2020.102478","volume":"85","author":"M Andrade-Campos","year":"2020","unstructured":"Andrade-Campos M, Escuder-Azuara B, De Frutos LL, Serrano-Gonzalo I, Giraldo P. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher disease patients in spain: time to reconsider home-based therapies? Blood Cells Molecules Dis. 2020;85:102478.","journal-title":"Blood Cells Molecules Dis"},{"key":"4221_CR68","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","volume":"32","author":"A Vellodi","year":"2009","unstructured":"Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin\u2010Histed T, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inher Metab Disea. 2009;32:660\u20134.","journal-title":"J Inher Metab Disea"},{"key":"4221_CR69","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3390\/jcm13102782","volume":"13","author":"P Deegan","year":"2024","unstructured":"Deegan P, Lau H, Elstein D, Fernandez-Sasso D, Giraldo P, Hughes D, et al. Long-Term treatment of Gaucher disease with velaglucerase Alfa in ERT-Na\u00efve patients from the Gaucher outcome survey (GOS) registry. JCM. 2024;13:2782.","journal-title":"JCM"},{"key":"4221_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2016.12.001","volume":"120","author":"A El-Beshlawy","year":"2017","unstructured":"El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the international collaborative Gaucher group Gaucher registry. Mol Genet Metab. 2017;120:47\u201356.","journal-title":"Mol Genet Metab"},{"key":"4221_CR71","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1067\/mpd.2001.112171","volume":"138","author":"G Altarescu","year":"2001","unstructured":"Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher\u2019s disease. J Pediatr. 2001;138:539\u201347.","journal-title":"J Pediatr"},{"key":"4221_CR72","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","volume":"132","author":"GA Grabowski","year":"2021","unstructured":"Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Gaucher disease: basic and translational science needs for more complete therapy and management. Mol Genet Metab. 2021;132:59\u201375.","journal-title":"Mol Genet Metab"},{"key":"4221_CR73","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.clinbiochem.2013.09.006","volume":"46","author":"P Ir\u00fan","year":"2013","unstructured":"Ir\u00fan P, Alfonso P, Aznarez S, Giraldo P, Pocovi M. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring. Clin Biochem. 2013;46:1804\u20137.","journal-title":"Clin Biochem"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04221-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04221-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04221-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:36:58Z","timestamp":1781631418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04221-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4221"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04221-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval is considered unnecessary according to national regulations, as this is not a study but a literature review, and nonpatient-level data are managed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JdH has received speaking and scientific consultancy fees from Sanofi and Takeda. JJC is a full-time employee of Takeda Farmac\u00e9utica Espa\u00f1a S.A. without stock options. SdP and MGB are employees of Pharmacoeconomics & Outcomes Research Iberia (PORIB), a consultant company specializing in the evaluation and assessment of health care interventions, which has received financial support to develop the literature review. IV declares no conflicts of interest. JdH and IV declare that they have not received financial support for drafting or reviewing the present manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}